Twitter | Search | |
Search Refresh
Benjamin Besse Sep 9
Update on hyperprogressive disease (HPD) - pts with NSCLC treated w single agent IO 1️⃣ OA14.06 Italy n=257 HPD 20.6% 2️⃣ P1.04.70 South Korea n=73 HPD 12% 3️⃣ P1.04.81 Latin-America n=110 HPD 19.8% 4️⃣ P2.04-77 Canada n=40 HPD 15% 5️⃣ P2.01-46 South Korea n=83 HPD 19.2%
Reply Retweet Like
Robert C. Doebele Sep 8
Entrectinib vs. crizotinib RWE shows nearly double TTD and OS benefit.
Reply Retweet Like
Mat Callister Sep 9
Disappointing that the room is so empty at to see an inspiring talk from IASLC-award winning Emily Stone about Tobacco Control. Surely this is the most pressing issue at this conference.
Reply Retweet Like
Roberto Ferrara Sep 9
Lkb1 is prognostic in NSCLC from a large real world study. Indeed rather to look with so many efforts for a genomic biomarker to predict IO efficacy we would need a better understand of TME or blood to identify IO predictive biomarkers.
Reply Retweet Like
Benjamin Besse Sep 9
Present and Future of immunotherapy. Great discussion by ⁦
Reply Retweet Like
Robert C. Doebele Aug 28
Come check out our poster at . Puzzling case of lung cancer leads to breakthrough discovery
Reply Retweet Like
Santiago Viteri Sep 11
Meeting with the experts and learning from them while having some tapas
Reply Retweet Like
Ana Laura Ortega Sep 9
Great surgical randomized trial confirming benefits of VATS vs lobectomy in lung cancer, VIOLET trial ... Proud of my colleagues, thoracic surgeons, doing the best for our patients!💪
Reply Retweet Like
Rodrigo Lastra Sep 10
Finish my first This is my brief summary, my own take home: Thanks and ...
Reply Retweet Like
Hossein Borghaei, DO Sep 9
Love . Only place I can be with both of my clinical mentors, Joe Treat and Corey Langer. As a fellow, Fox Chase I trained with them, one big room each attending on either side and we would discuss cases, argue points and talk data. Sometimes I would let other fellows in!
Reply Retweet Like
David Ball AO Aug 22
Enjoying August downunder ⁦⁩. Next stop Barcelona ⁦
Reply Retweet Like
Benjamin Besse Sep 10
Surprise! 60% of pts taking TKI for at least 3 months against ALK+/EGFRmut/BRAFmut NSCLC have LOW plasmatic levels (< usual threshold). In these pts, % of resistance mutations is lower than expected. Dose escalation in these ‘resistant’ patients? Congrats
Reply Retweet Like
Suraj Samtani Sep 9
Happy to be part of this study presented at !!!
Reply Retweet Like
Lara Pijuan,MD PhD Sep 7
Reply Retweet Like
ELO Sep 9
Very interesting oral presentations in the Biology Session at . brilliant discussions by Dr Carretero, Dr Paik and Dr Deneji
Reply Retweet Like
Isabelle Opitz Sep 6
Mesothelioma Workshop tomorrow morning ! Dr Nowak presents Update on Immunotherapy!!
Reply Retweet Like
Vanita Noronha Sep 8
Not being there in person, I am just unable to follow so many exciting studies at . I need a highlights of the day or a top-10 or something. Please help!
Reply Retweet Like
Ben Solomon Sep 6
Multidisciplinary lung meeting outside and inside Sagrada Familia pre Looking forward to the meeting starting tomorrow!
Reply Retweet Like
Robert C. Doebele Sep 9
Best conference center feature ever.
Reply Retweet Like
Ben Solomon Sep 6
imparting his wisdom about the top 10 factors to a successful career in Academic Oncology
Reply Retweet Like